CL2015001148A1 - Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por cftr - Google Patents

Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por cftr

Info

Publication number
CL2015001148A1
CL2015001148A1 CL2015001148A CL2015001148A CL2015001148A1 CL 2015001148 A1 CL2015001148 A1 CL 2015001148A1 CL 2015001148 A CL2015001148 A CL 2015001148A CL 2015001148 A CL2015001148 A CL 2015001148A CL 2015001148 A1 CL2015001148 A1 CL 2015001148A1
Authority
CL
Chile
Prior art keywords
treatment
cftr
pharmaceutical compositions
diseases mediated
methods
Prior art date
Application number
CL2015001148A
Other languages
English (en)
Spanish (es)
Inventor
Marinus Jacobus Verwijs
Radhika Karkare
Michael Douglas Moore
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001148(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CL2015001148A1 publication Critical patent/CL2015001148A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2015001148A 2012-11-02 2015-04-30 Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por cftr CL2015001148A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261721622P 2012-11-02 2012-11-02
US201261728328P 2012-11-20 2012-11-20
US201361770668P 2013-02-28 2013-02-28
US201361824005P 2013-05-16 2013-05-16
US201361840668P 2013-06-28 2013-06-28

Publications (1)

Publication Number Publication Date
CL2015001148A1 true CL2015001148A1 (es) 2016-02-19

Family

ID=50628072

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001148A CL2015001148A1 (es) 2012-11-02 2015-04-30 Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por cftr

Country Status (30)

Country Link
US (4) US20140163068A1 (enExample)
EP (3) EP2914248B2 (enExample)
JP (4) JP6302923B2 (enExample)
KR (1) KR102396897B1 (enExample)
CN (2) CN104869982A (enExample)
AR (1) AR093340A1 (enExample)
AU (4) AU2013337730B2 (enExample)
BR (1) BR112015009913B1 (enExample)
CA (1) CA2890106C (enExample)
CL (1) CL2015001148A1 (enExample)
CY (1) CY1121070T1 (enExample)
DK (2) DK3470063T3 (enExample)
ES (2) ES2694290T5 (enExample)
FI (2) FI2914248T4 (enExample)
HR (2) HRP20250100T1 (enExample)
HU (2) HUE039864T2 (enExample)
IL (2) IL283276B2 (enExample)
LT (2) LT2914248T (enExample)
MX (2) MX368353B (enExample)
NZ (2) NZ708474A (enExample)
PL (2) PL2914248T5 (enExample)
PT (2) PT2914248T (enExample)
RS (2) RS66596B1 (enExample)
SG (3) SG10201703452PA (enExample)
SI (2) SI3470063T1 (enExample)
SM (2) SMT202500078T1 (enExample)
TR (1) TR201815218T4 (enExample)
TW (2) TW201422253A (enExample)
UA (2) UA117464C2 (enExample)
WO (1) WO2014071122A1 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002567A (es) 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
MX2008002019A (es) 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
NZ596889A (en) 2006-04-07 2013-06-28 Vertex Pharma Use of amide indole derivatives as modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CN102863432B (zh) 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
HUE028426T2 (en) 2007-08-24 2016-12-28 Vertex Pharma Isothiazolopyridinones for (inter alia) treating cystic fibrosis
ES2556080T3 (es) 2007-11-16 2016-01-12 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
KR20150063170A (ko) 2007-12-07 2015-06-08 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CN106432213A (zh) 2008-02-28 2017-02-22 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
MX384179B (es) 2009-03-20 2025-03-14 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN102933206A (zh) 2010-04-07 2013-02-13 弗特克斯药品有限公司 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
KR101985044B1 (ko) 2011-11-08 2019-05-31 버텍스 파마슈티칼스 인코포레이티드 Atp-결합 카세트 수송체의 조절제
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
DK2806859T3 (da) 2012-01-25 2019-08-05 Vertex Pharma Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
SMT202500078T1 (it) * 2012-11-02 2025-03-12 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
US9303918B2 (en) * 2013-03-15 2016-04-05 Monosol Rx, Llc Process for drying a wet film with control of loss on drying
WO2014176553A1 (en) * 2013-04-26 2014-10-30 Vertex Pharmaceuticals Incorporated Correctors acting through msd1 of cftr protein
DK3068392T5 (da) * 2013-11-12 2021-09-20 Vertex Pharma Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016081556A1 (en) 2014-11-18 2016-05-26 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
CA2984480A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
MA42954A (fr) 2015-09-25 2018-08-01 Vertex Pharmaceuticals Europe Ltd Potentialisateurs cftr deutérés
WO2017151725A1 (en) * 2016-03-03 2017-09-08 Nivalis Therapeutics, Inc. Formulations of an s-nitrosoglutathione reductase inhibitor
EP3436446B1 (en) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10376501B2 (en) 2016-04-25 2019-08-13 Druggability Technologies Ip Holdco Limited Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600270A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
HUP1600271A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600269A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
US10206915B2 (en) 2016-04-25 2019-02-19 Druggability Technologies Ip Holdco Limited Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
SG10201913595YA (en) 2016-09-30 2020-02-27 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3541807B1 (en) 2016-11-16 2021-09-29 H. Lundbeck A/S A crystalline form of a magl inhibitor
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
MA49235B1 (fr) 2016-12-09 2021-02-26 Vertex Pharma Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
EP3634402B1 (en) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
SG11202004264VA (en) 2017-12-01 2020-06-29 Vertex Pharma Processes for making modulators of cystic fibrosis transmembrane conductance regulator
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3752510B1 (en) 2018-02-15 2022-12-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
WO2019195739A1 (en) 2018-04-05 2019-10-10 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2019381750B2 (en) 2018-11-14 2025-08-07 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
MX2022001827A (es) 2019-08-14 2022-06-09 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica.
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
WO2022194399A1 (en) 2020-07-13 2022-09-22 Idorsia Pharmaceuticals Ltd Macrocycles as cftr modulators
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3188787A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
CN116670143A (zh) 2020-10-07 2023-08-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控因子的调节剂
WO2022076626A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225737A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225748A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230382924A1 (en) 2020-10-07 2023-11-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225750A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230374038A1 (en) 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076618A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CR20230198A (es) 2020-10-07 2023-07-03 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
TW202233635A (zh) 2020-10-07 2022-09-01 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US20240100183A1 (en) * 2020-12-11 2024-03-28 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
CA3211232A1 (en) * 2021-03-09 2022-09-15 Hemant Bhagwat NARKHEDE Oral film of cftr modulator(s)
JP2025506382A (ja) 2022-02-03 2025-03-11 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の治療方法
AU2023218262A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20250008540A (ko) 2022-04-06 2025-01-14 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막관통 전도도 조절자의 조절제
CA3253026A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated TREATMENT METHODS FOR CYSTIC FIBROSIS
JP2025529476A (ja) 2022-09-15 2025-09-04 イドルシア・ファーマシューティカルズ・リミテッド （３Ｓ，７Ｓ，１０Ｒ，１３Ｒ）－１３－ベンジル－２０－フルオロ－７－イソブチル－Ｎ－（２－（３－メトキシ－１，２，４－オキサジアゾール－５－イル）エチル）－６，９－ジメチル－１，５，８，１１－テトラオキソ－１０－（２，２，２－トリフルオロエチル）－１，２，３，４，５，６，７，８，９，１０，１１，１２，１３，１４－テトラデカヒドロ－［１］オキサ［４，７，１０，１４］テトラアザシクロヘプタデシノ［１６，１７－ｆ］キノリン－３－カルボキサミドの結晶形
WO2024056791A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
CN119894906A (zh) 2022-09-15 2025-04-25 爱杜西亚药品有限公司 大环cftr调节剂
WO2025076235A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
JP4977319B2 (ja) 2002-09-30 2012-07-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 嚢胞性線維症膜コンダクタンス制御因子蛋白質阻害薬およびその使用方法
US20050113423A1 (en) 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
EP3345895B1 (en) 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
US7696244B2 (en) 2003-05-16 2010-04-13 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
AU2004279855A1 (en) 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups
EP1682127B1 (en) 2003-11-14 2009-07-29 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
AU2005228685B2 (en) 2004-03-30 2010-08-19 The Regents Of The University Of California Hydrazide-containing CFTR inhibitor compounds and uses thereof
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
WO2006044456A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
EP1865949B1 (en) 2005-03-11 2012-11-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2600869A1 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
JP5426878B2 (ja) 2005-05-24 2014-02-26 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ−結合カセットトランスポーターのモジュレーター
CN101312722A (zh) 2005-10-06 2008-11-26 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
US8318935B2 (en) 2007-05-07 2012-11-27 Novartis Ag Organic compounds 75074
RU2010114732A (ru) * 2007-09-14 2011-10-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида
KR20150063170A (ko) 2007-12-07 2015-06-08 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
LT3345625T (lt) 2008-08-13 2021-02-10 Vertex Pharmaceuticals Incorporated Farmacinė kompozicija ir jos vartojimas
AU2009296271A1 (en) * 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN102803234A (zh) * 2009-06-02 2012-11-28 霓坎制药有限责任公司 用于治疗疾病的人甲酰基肽受体的拮抗作用
JP2011034380A (ja) * 2009-08-03 2011-02-17 Nitto Denko Corp タッチパネルおよびタッチパネル付表示装置
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
BR112012026255A2 (pt) * 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
AU2011242452A1 (en) * 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US10105356B2 (en) * 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
DK2806859T3 (da) * 2012-01-25 2019-08-05 Vertex Pharma Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
SMT202500078T1 (it) * 2012-11-02 2025-03-12 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
DK3068392T5 (da) * 2013-11-12 2021-09-20 Vertex Pharma Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme

Also Published As

Publication number Publication date
IL283276B1 (en) 2024-01-01
SMT201800590T1 (it) 2019-01-11
CA2890106A1 (en) 2014-05-08
SG10201703452PA (en) 2017-06-29
MX2015005559A (es) 2015-10-29
HUE039864T2 (hu) 2019-02-28
ES2694290T3 (es) 2018-12-19
AU2020204037B2 (en) 2023-10-19
RU2692676C2 (ru) 2019-06-26
IL238551A0 (en) 2015-06-30
UA117464C2 (uk) 2018-08-10
SMT202500078T1 (it) 2025-03-12
HRP20181740T4 (hr) 2024-01-05
RS57831B1 (sr) 2018-12-31
EP2914248B2 (en) 2023-10-18
BR112015009913B1 (pt) 2023-04-11
SG11201503365YA (en) 2015-06-29
SI2914248T2 (sl) 2023-12-29
IL283276B2 (en) 2024-05-01
PT2914248T (pt) 2018-11-29
FI2914248T4 (fi) 2023-12-19
JP2018090626A (ja) 2018-06-14
AU2024200273A1 (en) 2024-02-01
KR102396897B1 (ko) 2022-05-13
EP3470063B1 (en) 2025-01-01
HRP20181740T1 (hr) 2018-12-28
AU2013337730B2 (en) 2018-06-14
US20200338063A1 (en) 2020-10-29
RS66596B1 (sr) 2025-04-30
WO2014071122A1 (en) 2014-05-08
SI3470063T1 (sl) 2025-04-30
MX2019011662A (es) 2019-11-18
HK1212632A1 (en) 2016-06-17
MX368353B (es) 2019-09-30
AU2020204037A1 (en) 2020-07-09
IL238551B (en) 2021-06-30
EP2914248B1 (en) 2018-09-05
DK3470063T3 (da) 2025-01-20
PL3470063T3 (pl) 2025-04-14
TWI736768B (zh) 2021-08-21
DK2914248T3 (en) 2018-11-26
SI2914248T1 (sl) 2018-12-31
JP2022034069A (ja) 2022-03-02
EP2914248A1 (en) 2015-09-09
SG10201913581UA (en) 2020-02-27
PL2914248T3 (pl) 2019-01-31
EP4556008A3 (en) 2025-08-27
PL2914248T5 (pl) 2024-01-15
LT3470063T (lt) 2025-02-10
IL283276A (en) 2021-07-29
RU2019117882A (ru) 2019-10-04
TW201422253A (zh) 2014-06-16
CA2890106C (en) 2022-08-02
US20160324846A1 (en) 2016-11-10
UA123631C2 (uk) 2021-05-05
KR20150080609A (ko) 2015-07-09
JP2019142956A (ja) 2019-08-29
JP7003085B2 (ja) 2022-02-04
CN104869982A (zh) 2015-08-26
HUE070382T2 (hu) 2025-06-28
TW201842907A (zh) 2018-12-16
ES2694290T5 (es) 2024-05-21
JP2015535289A (ja) 2015-12-10
FI3470063T3 (fi) 2025-03-05
HRP20250100T1 (hr) 2025-03-28
ES3009747T3 (en) 2025-03-31
AU2013337730A1 (en) 2015-06-11
RS57831B2 (sr) 2024-02-29
US20230364073A1 (en) 2023-11-16
NZ745659A (en) 2020-04-24
BR112015009913A8 (pt) 2019-09-17
CY1121070T1 (el) 2020-05-29
US20140163068A1 (en) 2014-06-12
JP6302923B2 (ja) 2018-03-28
NZ708474A (en) 2019-02-22
BR112015009913A2 (pt) 2017-07-11
TR201815218T4 (tr) 2018-11-21
AU2018229528A1 (en) 2018-10-11
PT3470063T (pt) 2025-03-10
RU2015120798A (ru) 2016-12-27
EP4556008A2 (en) 2025-05-21
EP3470063A1 (en) 2019-04-17
AR093340A1 (es) 2015-06-03
DK2914248T4 (da) 2024-01-02
CN111671751A (zh) 2020-09-18
LT2914248T (lt) 2018-11-26

Similar Documents

Publication Publication Date Title
CL2015001148A1 (es) Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por cftr
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
PL2806859T3 (pl) Formulacje kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5- ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
EP3040072A4 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
MX2016006118A (es) Proceso para preparar composiciones farmaceuticas para el tratamiento de enfermedades mediadas por regulador de la conductancia transmembrana de la fibrosis quistica (cftr).
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
PT2811998T (pt) Composições veterinárias orais parasiticidas compreendendo agentes activos de actuação sistémica, métodos e as suas utilizações
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX373713B (es) Compuestos pirazolopirimidina.
CL2014000447A1 (es) Compuestos derivados de piridina y pirimidina sustituidos, mediadores de quinurenina-3-monooxigenasa; composiciones farmaceuticas que los comprenden; y uso en el tratamiento de una patologia neurodegenerativa, tal como la enfermedad de huntington.
GT201400111A (es) Triazolopiridinas sustituidas
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
IN2014DN09347A (enExample)
EP3037093A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
CO7200259A2 (es) Nuevos derivados de piridina
CL2014000850A1 (es) Derivados de heterociclilpiri(mi) dinilpirazoles; composicion para combatir hongos; procedimiento para combatir hongos.
AP4077A (en) Use of derivative compounds of 1,3-benzodioxole in insecticidal compositions
IN2013MU02442A (enExample)